Legend Biotech Corporation

NasdaqGS:LEGN 株式レポート

時価総額:US$7.4b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Legend Biotech 将来の成長

Future 基準チェック /66

Legend Biotech利益と収益がそれぞれ年間63.7%と36.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に28.1% 69.4%なると予測されています。

主要情報

63.7%

収益成長率

69.4%

EPS成長率

Biotechs 収益成長24.5%
収益成長率36.4%
将来の株主資本利益率28.1%
アナリストカバレッジ

Good

最終更新日18 Jun 2024

今後の成長に関する最新情報

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Mar 22
Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Recent updates

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

May 14

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

May 13
Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

Mar 15

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Mar 06
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Legend Biotech: Solid Traction With Carvykti Rollout

Jan 29

Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Jan 16
Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Nov 09
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Apr 12
Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Dec 14
An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Sep 27

Legend Biotech stock slides on proposed ADS offering

Jul 25

Legend Biotech ends Phase 1 trial for lymphoma candidate

Jul 07

News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Jun 05
News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

May 14
Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Mar 22
Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Legend Biotech: Carvykti Approval Makes For A Buy Opportunity

Mar 04

Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Mar 03
Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Dec 30
Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Calculating The Intrinsic Value Of Legend Biotech Corporation (NASDAQ:LEGN)

Nov 22
Calculating The Intrinsic Value Of Legend Biotech Corporation (NASDAQ:LEGN)

Is Legend Biotech (NASDAQ:LEGN) Using Debt Sensibly?

Aug 26
Is Legend Biotech (NASDAQ:LEGN) Using Debt Sensibly?

Analysts Have Just Cut Their Legend Biotech Corporation (NASDAQ:LEGN) Revenue Estimates By 18%

Jun 11
Analysts Have Just Cut Their Legend Biotech Corporation (NASDAQ:LEGN) Revenue Estimates By 18%

業績と収益の成長予測

NasdaqGS:LEGN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20261,56115415618114
12/31/20251,028-153-154-19719
12/31/2024551-323-408-16319
3/31/2024343-466-264-239N/A
12/31/2023285-518-416-393N/A
9/30/2023233-509-371-347N/A
6/30/2023165-532-378-359N/A
3/31/2023112-517-276-262N/A
12/31/2022117-446-224-201N/A
9/30/2022106-416-237-221N/A
6/30/202296-457-221-194N/A
3/31/2022119-346-293-250N/A
12/31/202169-404-244-198N/A
9/30/202193-356-245-185N/A
6/30/202189-297-259-205N/A
3/31/202180-340-256-204N/A
12/31/202075-266-253-223N/A
9/30/202059-310-300-227N/A
6/30/202064-271-209-143N/A
3/31/202061-165-160-125N/A
1/1/202062-102-110-83N/A
12/31/201849-3287308N/A
12/31/2017249N/A-2N/A

アナリストによる今後の成長予測

収入対貯蓄率: LEGNは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: LEGN今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: LEGN今後 3 年以内に収益を上げることが予想されます。

収益対市場: LEGNの収益 ( 36.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: LEGNの収益 ( 36.4% ) 20%よりも速いペースで成長すると予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: LEGNの 自己資本利益率 は、3年後には高くなると予測されています ( 28.1 %)


成長企業の発掘